Medical device company Integra LifeSciences (NASDAQ:IART) reported Q2 CY2025 results , but sales were flat year on year at ...

Integra Lifesciences Holdings Corp (NASDAQ:IART) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus ...

Medical device company Integra LifeSciences (NASDAQ:IART) will be reporting results this Thursday before market open. Here’s ...

For the current quarter ending in September, Integra expects its per-share earnings to range from 40 cents to 45 cents. The company said it expects revenue in the range of $410 million to $420 million ...

Integra LifeSciences (Nasdaq: IART) shares are on the rise today on second-quarter results that beat the consensus forecast.

Integra LifeSciences Holdings Corporation (IART) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

For the quarter ended December 2024, Integra LifeSciences (IART) reported revenue of $442.65 million, up 11.5% over the same period last year. EPS came in at $0.97, compared to $0.89 in the year ...

Another notable valuation metric for IART is its P/B ratio of 1.18. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus ...

Another notable valuation metric for IART is its P/B ratio of 1.28. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.